Treatment of Ectopic Calcification / Ossification With Sodium Thiosulfate (CATSSO)
1 other identifier
observational
120
1 country
7
Brief Summary
Ectopic calcification and ossification complicate many diseases, which are rare for the most part. These calcifications (or ossifications) are generally classified according to their apparent formation mechanism. Even if very different diseases can be at the origin, these calcifications (or ossifications) have as common points: an unknown physiopathology, a composition of calcium pyrophosphate for the most part and l no curative treatment validated to date. Indeed, although several reported cases suggest the potential efficacy of different treatments , none of these treatments is currently recognized as effective because of the absence of confirmation data or because of contradictory results. Sodium thiosulfate (STS) has been used for a long time as an antidote to cyanide poisoning and as a protective agent against cytotoxic side effects such as ifosphamide. More recently, STS has been reported in the treatment of renal calcification. vascular or even subcutaneous. First prospective studies on animal models and in humans seem to confirm the interest of this product in the treatment of these abnormal calcifications. For several months, a magistral preparation in the form of ointment based on STS has been developed by the pharmacy of Limoges University Hospital in order to combine the local effect of STS while avoiding the side effects of an administration of this treatment by systemic way. The first uses of this preparation appear promising and some preliminary results have already been published. The benefit / risk ratio of this approach seems to be advantageous for clinicians since preparations whose composition is close are currently validated by the FDA and the World Health Organisation for the treatment of benign pathologies such as cutaneous dermatophytes or pityriasis versicolor.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2015
Longer than P75 for all trials
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2015
CompletedFirst Submitted
Initial submission to the registry
June 4, 2019
CompletedFirst Posted
Study publicly available on registry
June 7, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2020
CompletedJune 11, 2019
June 1, 2019
5 years
June 4, 2019
June 7, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Calcification/Ossification volume
Percentage decrease in the volume or surface area of calcifications (or ossification) treated on imaging of the same type performed before and 6 months after dermal STS use.
Month 6
Secondary Outcomes (4)
Change in aesthetic evolution from baseline at 6 month
Day 0, Month 6
Change in pain from baseline at 6 month
Day 0, Month 6
Change of the quality of life from baseline at 6 month
Day 0, Month 6
local or general side effects
Month 6
Eligibility Criteria
patient with ectopic calcification / ossification
You may qualify if:
- any patient treated with sodium thiosulfate dermally provided by the pharmacy of Limoges University Hospital.
- availability of an objective imaging evaluation to compare the volume or surface of calcifications (or ossifications) treated (on two orthogonal incidences) before and after 6 months of treatment application.
- consent to participation in the study signed by the patient or by one of the holders of parental authority in the case of a minor patient.
You may not qualify if:
- calcification with concomitant cutaneous rupture which can allow an externalization of the calcium material by mechanical effects.
- Patient with calcification secondary to one of the following pathologies:
- diabetes
- chronic renal failure
- iatrogenic origin
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (7)
Grenoble university hospital
Grenoble, France
Kremlin Bicetre Hospital
Le Kremlin-Bicêtre, France
CHU de Limoges
Limoges, France
HEGP
Paris, France
Lariboisière Hospital
Paris, France
Necker Hospital
Paris, France
Robert Debré Hospital
Paris, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 4, 2019
First Posted
June 7, 2019
Study Start
February 1, 2015
Primary Completion
February 1, 2020
Study Completion
February 1, 2020
Last Updated
June 11, 2019
Record last verified: 2019-06